Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16171 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
filingDate |
2017-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2019526580-A |
titleOfInvention |
Method for eliciting an immune response against human immunodeficiency virus infection in a subject undergoing antiretroviral treatment |
abstract |
A method for eliciting an immune response against human immunodeficiency virus (HIV) in a subject infected with HIV undergoing antiretroviral therapy (ART) is described. The method comprises administering a primer vaccine of an adenoviral vector and a booster vaccine of a modified vaccinia virus (MVA) vector encoding a mosaic HIV antigen. |
priorityDate |
2016-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |